Medicine for treating ischemia reperfusion injury and application thereof

By preparing mesenchymal stem cell exosomes with upregulated CCL2 protein expression, the CCR2/GNAI2/PI3K-Akt signaling axis was activated, synergistically regulating the Nrf2-driven antioxidant defense system and the Bcl-2-mediated anti-apoptotic pathway. This solved the problem of targeted therapy for testicular ischemia-reperfusion injury, significantly improved testicular structure and function, and enhanced spermatogenesis.

CN122297522APending Publication Date: 2026-06-30THE 910TH HOSPITAL OF THE CHINESE PEOPLES LIBERATION ARMY JOINT LOGISTICS SUPPORT FORCE +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202610524650.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-20
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

There are currently no targeted therapies for treating testicular ischemia-reperfusion injury, which leads to severe secondary tissue damage and affects fertility. Furthermore, the application of mesenchymal stem cell exosomes in this scenario suffers from problems such as high component heterogeneity, unstable efficacy, and insufficient targeting and consistency of effects.

Method used

By preparing mesenchymal stem cell exosomes with upregulated CCL2 protein expression (H2S-Exos), the CCR2/GNAI2/PI3K-Akt signaling axis was activated, synergistically regulating the Nrf2-driven antioxidant defense system and the Bcl-2-mediated anti-apoptotic pathway, thus treating testicular ischemia-reperfusion injury.

Benefits of technology

It significantly improves the structural and functional integrity of the testes, maintains sperm motility, reduces ischemia-reperfusion injury, and enhances testicular spermatogenesis and fertility.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a medicine for treating ischemia-reperfusion injury and application thereof, and provides a medicine for treating ischemia-reperfusion injury, the medicine activates a CCL2-chemokine receptor 2 signal axis, triggers a downstream G protein alphai2 subunit mediated phosphatidylinositol 3-kinase / protein kinase B signal channel, and can be used for treating ischemia-reperfusion injury. Further, an anti-oxidation defense system driven by a nuclear factor erythroid 2 related factor 2 and an anti-apoptosis pathway mediated by B cell lymphoma 2 are cooperatively regulated and controlled, so that the ischemia-reperfusion injury is treated. According to the research result, a novel treatment strategy for testis ischemia reperfusion injury based on the engineered exosome is established, and meanwhile, the cell protection effect of a CCL2 / CCR2 signal axis in non-immune cells which is not found yet is disclosed.
Need to check novelty before this filing date? Find Prior Art